86984-32-9

Basic information

• Product Name: 6-CHLORO-5-NITROQUINOLINE
• Synonyms: 6-CHLORO-5-NITROQUINOLINE;Quinoline, 6-chloro-5-nitro-
• CAS NO: 86984-32-9
• Molecular Formula: C₉H₅ClN₂O₂
• Molecular Weight: 208.6
• Mol File: 86984-32-9.mol

Chemical Properties

• Boiling Point: 356.7 °C at 760 mmHg
• Flash Point: 169.5 °C
• Appearance: /
• Density: 1.484 g/cm³
• Vapor Pressure: 5.9E-05mmHg at 25°C
• Refractive Index: 1.688
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 2.02±0.15(Predicted)
• CAS DataBase Reference: 6-CHLORO-5-NITROQUINOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-CHLORO-5-NITROQUINOLINE(86984-32-9)
• EPA Substance Registry System: 6-CHLORO-5-NITROQUINOLINE(86984-32-9)

Safety Data

• Hazardous Substances Data: 86984-32-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Chloro-5-nitroquinoline is used as an intermediate in the production of various pharmaceuticals for its potential role in the development of new drugs and therapeutic agents. Its anti-inflammatory, antimicrobial, and antiproliferative properties contribute to its value in this application.
Used in Agrochemical Industry:
6-Chloro-5-nitroquinoline is utilized as an intermediate in the synthesis of agrochemicals, where its properties can be harnessed to develop effective solutions for agricultural applications.
Used in Dye Industry:
As a quinoline derivative, 6-chloro-5-nitroquinoline is used in the production of dyes, taking advantage of its chemical structure to create a range of colorants for various industries.
Used in Optoelectronic Applications:
6-Chloro-5-nitroquinoline is employed in the fabrication of organic light-emitting devices and other optoelectronic applications due to its photophysical properties, which make it a valuable component in these high-tech devices.

InChI:InChI=1/C9H5ClN2O2/c10-7-3-4-8-6(2-1-5-11-8)9(7)12(13)14/h1-5H

Upstream product

• 612-57-7 6-chloroquinoline 
• 635-22-3 4-Chloro-3-nitroaniline 
• 56-81-5 glycerol 
• 106-47-8 4-chloro-aniline 

Downstream Products

• 1080521-25-0 2-(4-(5-(4-chlorophenylsulfonamido)-2-oxo-1,2-dihydroquinolin-6-yloxy)-3-methoxyphenyl)acetic acid 
• 1080521-24-9 2-(4-(5-(4-chlorophenylsulfonamido)quinolin-6-yloxy)-3-methoxyphenyl)acetic acid 
• 1080522-78-6 ethyl 2-(3-methoxy-4-(5-nitro-2-oxo-1,2-dihydroquinolin-6-yloxy)phenyl)acetate 
• 1080522-79-7 ethyl 2-(4-(5-amino-2-oxo-1,2-dihydroquinolin-6-yloxy)-3-methoxyphenyl)acetate 
• 1080522-75-3 ethyl 2-(3-methoxy-4-(5-nitro-1N-oxide-quinolin-6-yloxy)phenyl)acetate 
• 1080522-72-0 ethyl 2-(3-methoxy-4-(5-nitroquinolin-6-yloxy)phenyl)acetate 
• 1080522-74-2 ethyl 2-(4-(5-aminoquinolin-6-yloxy)-3-methoxyphenyl)acetate 
• 1080522-70-8 2-(3-methoxy-4-(5-nitroquinolin-6-yloxy)phenyl)acetic acid 
• 606-42-8 5,6-dichloro-quinoline 
• 687616-04-2 5-amino-6-(4-methoxybenzylamino)quinoline 
• 100672-24-0 3H-3-(4-methoxyphenylmethyl)-2-(4-methoxyphenyl)imidazo<4,5-f>quinoline 
• 341010-40-0 5-Amino-6-chlorchinolin 
• 190331-45-4 4-(5-nitro-[6]quinolylmercapto)-aniline 
• 100672-30-8 5-nitro-6-(4-methoxybenzylamino)quinoline 

Relevant articles and documents

Cell necrosis inhibitor, and preparation method and application thereof

The invention provides a cell necrosis inhibitor, and a preparation method and application thereof. Particularly, the invention provides an inhibitor for inhibiting cell necrosis and/or human receptorinteracting protein 1 kinase (RIP1). The inhibitor has

A Molecular Hybridization Approach for the Design of Potent, Highly Selective, and Brain-Penetrant N-Myristoyltransferase Inhibitors

Crystallography has guided the hybridization of two series of Trypanosoma brucei N-myristoyltransferase (NMT) inhibitors, leading to a novel highly selective series. The effect of combining the selectivity enhancing elements from two pharmacophores is shown to be additive and has led to compounds that have greater than 1000-fold selectivity for TbNMT vs HsNMT. Further optimization of the hybrid series has identified compounds with significant trypanocidal activity capable of crossing the blood-brain barrier. By using CF-1 mdr1a deficient mice, we were able to demonstrate full cures in vivo in a mouse model of stage 2 African sleeping sickness. This and previous work provides very strong validation for NMT as a drug target for human African trypanosomiasis in both the peripheral and central nervous system stages of disease.

COMPOUNDS AND METHODS USEFUL FOR TREATING ASTHMA AND ALLERGIC INFLAMMATION

Compounds, compositions and methods that are useful in the treatment of inflammatory and immune-related diseases and conditions are provided herein. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives.

4-aryl-3-(heteroarylureido)quinoline derivatves

Compounds of the formula STR1 and the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, m, X and Q are as defined below, and novel intermediates used in the synthesis of such compounds. The comp

Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)

Compounds of the formula STR1 wherein R21 and R22 are as defined in the specification which are intermediates useful in the preparation of compounds of the formula STR2 and the pharmaceutically acceptable salts thereof, wherein Q and R1 are as defined in the specification. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.

New N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase

Compounds of the formula the pharmaceutically acceptable salts thereof, wherein Q and R1 are as defined below, and novel carboxylic acid and acid halide intermediates used in the synthesis of such compounds. The compounds of formula I are inhibitors of acyl coenzyme A: cholesterol acyltransferase (ACAT) and are useful as hypolipidemic and antiatherosclerosis agents.